Docoh
Loading...

GIDYL Gi Dynamics

GI Dynamics® Inc. (ASX:GID) is the developer of EndoBarrier®, the first endoscopically delivered medical device for the treatment of type 2 diabetes and the reduction of obesity. EndoBarrier is not approved for sale and is limited by federal law to investigational use only. EndoBarrier is subject to an Investigational Device Exemption by the FDA in the United States and is entering concurrent pivotal trials in the United States and India.

Company profile

Ticker
GIDYL
Exchange
CEO
Scott W. Schorer
Employees
Incorporated
Location
Fiscal year end
Former names
GI DYNAMICS INC
SEC CIK

GIDYL stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

11 Jun 21
23 Oct 21
31 Dec 21
Quarter (USD)
Mar 21 Dec 20 Sep 20 Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Gi Dynamics earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 961K 961K 961K 961K 961K 961K
Cash burn (monthly) 76K 243.58K 789.67K 887.08K 580K 778.67K
Cash used (since last report) 512.36K 1.64M 5.32M 5.98M 3.91M 5.25M
Cash remaining 448.64K -681.13K -4.36M -5.02M -2.95M -4.29M
Runway (months of cash) 5.9 -2.8 -5.5 -5.7 -5.1 -5.5

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
9 Mar 21 Charles Ross Carter Stock Option Common Stock Sale back to company Dispose D No No 1.1204 385,226 431.61K 0
28 Jan 21 Joseph Virgilio Iii Stock Option Common Stock Grant Acquire A No No 0.06 11,075,869 664.55K 11,075,869
28 Jan 21 Mark D Lerdal Stock Option Common Stock Grant Acquire A No No 0.06 1,384,483 83.07K 1,384,483

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

13F holders
Current Prev Q Change
Total holders 0 0
Opened positions 0 0
Closed positions 0 0
Increased positions 0 0
Reduced positions 0 0
13F shares
Current Prev Q Change
Total value 0 0
Total shares 0 0
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Largest transactions
Shares Bought/sold Change

Financial report summary

?
Management Discussion
  • GI Dynamics did not record any revenue in the years ended December 31, 2020 or 2019.
  • Research and Development Expense. The decrease in research and development expense of approximately $741 thousand for the year ended December 31, 2020 compared to the year ended December 31, 2019 was primarily due to a decrease in spending on internal and external resources as the COVID-19 pandemic caused clinical pauses on trial enrollment and slowed international regulatory reviews to start the I-Step Trial and perform CE mark certification audits. In 2019 the Company incurred expenses to prepared for and initiate the STEP-1 clinical trial in the United States, the I-STEP trial in India (under joint venture with Apollo Sugar) and prepare for audits related to filing for its CE Mark designation.
  • Sales and Marketing Expense. The decrease in sales and marketing expense of approximately $22 thousand for the year ended December 31, 2020 compared to the year ended December 31, 2019 was primarily due to limited spending on sales and marketing given COVID-19 pandemic delays and the focus of resources on a marketing project that remains a prepaid expense until fully implemented.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Bad
New words: capacity, Carter, categorization, China, clearance, collectively, disallowed, fatigue, Fexpense, global, governmental, inability, longer, magnitude, multiple, pause, perception, personnel, procedure, reduction, reply, sector, societal, strain, strike, submission, surfaced, tolerance, Treasurer, uneven, vaccine, Wuhan
Removed: accrual, added, applied, assessed, assign, ASU, Australia, award, awarded, beginning, classified, closing, Collateral, comparable, component, concentration, consideration, consist, deal, declined, delivered, Depositary, disclose, disclosing, Dr, effectually, elimination, ending, enter, explicit, exposure, facility, fiduciary, fluctuation, foreign, fulfillment, guidance, hand, Healthcare, hold, inflation, insurance, intrinsic, invest, leased, likelihood, maintained, maximize, measurement, membership, methodology, MHRA, milestone, minimal, mitigate, Modified, monthly, multiplied, narrative, NED, occupancy, ongoing, owner, percentage, policy, Praveen, preservation, prospectively, PSU, quality, range, rating, redemption, relevant, remeasured, remote, requirement, retrospectively, reversed, satisfaction, sensitivity, settled, shown, speculative, spending, tax, Topic, transfer, Tyle, uncured, unit, unrealized, unvested, vesting, WeWork, write

Patents

APP
Utility
Devices and Methods for Placing a Gastrointestinal Device
22 Jul 21
A delivery system for placing a gastrointestinal device in a mammalian gastrointestinal tract comprises a container assembly; a gastrointestinal implant device that includes proximal and distal ends stored within the container assembly, the proximal end including an anchor and the distal end including a sleeve, coupled to the anchor and folded into the container assembly; and an inner extension to draw a portion of the sleeve from the anchor and from the container assembly as the anchor is retained therein.
APP
Utility
Gastrointestinal Implant Delivery Systems and Methods
8 Jul 21
The present invention provides delivery systems for positioning a gastrointestinal implant in a patient, for example, for treatment of a metabolic disease.
GRANT
Utility
Flanged gastrointestinal devices and methods of use thereof
8 Jun 21
The present invention provides gastrointestinal devices for limiting transfer and contact of material across luminal walls along a segment of the gastrointestinal tract (e.g., at the duodenum and/or upper jejunum).
GRANT
Utility
Transpyloric anchoring
11 May 21
A gastrointestinal implant device (2800) comprises a planar proximal element (220) configured to reside in a stomach to resist distal migration, a distal element (222) configured to reside in an intestine to resist proximal migration and one or more tethers (224) coupling the planar proximal element to the distal element.
APP
Utility
Transpyloric Anchoring
25 Mar 21
Gastrointestinal implants can be used to secure thin-walled sleeves, restrictor plates, and other devices within the gastrointestinal tract.